![Share on Facebook Facebook](https://mcandrewslaw.com/wp-content/plugins/social-media-feather/synved-social/image/social/regular/32x32/facebook.png)
![Share on Twitter twitter](https://mcandrewslaw.com/wp-content/plugins/social-media-feather/synved-social/image/social/regular/32x32/twitter.png)
![Pin it with Pinterest pinterest](https://mcandrewslaw.com/wp-content/plugins/social-media-feather/synved-social/image/social/regular/32x32/pinterest.png)
![Share on Linkedin linkedin](https://mcandrewslaw.com/wp-content/plugins/social-media-feather/synved-social/image/social/regular/32x32/linkedin.png)
Legislation introduced on Monday in both houses of Congress would require generic-drug makers to give rebates to Medicaid when prices rise faster than inflation, the latest salvo in an escalating national debate around prescription drug spending. Sen. Bernie Sanders (I-VT) and Rep. Elijah Cummings (D-MD) introduced the Medicaid Generic Drug Price Fairness Act to address the problem of soaring generic-drug prices charged to Medicaid. The bill would extend an existing rebate requirement for brand-name drugs to their no-name counterparts.